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SummarieS
noVel and tarGeted therapieS
Preliminary report on tumor stem cell/B cell 
hybridoma vaccine for recurrent glioblastoma 
multiforme
In a open study, Moviglia and colleagues evenly divided 12 cons
secutive patients into 3 groups, each group receiving one of three 
different treatments:  the first four patients received debulking 
surgery (DS) plus radiotherapy (Rx) and after the first relapse, 
DS plus mixed leukocyte culture (MLC); the next four patients 
received DS plus Rx and after the first relapse underwent DS plus 
MLC plus tumor B cell hybridoma (TBH) vaccination; the last 
four patients received DS plus Rx and after first relapse underwent 
DS plus TBH vaccination. In the first two groups, the treatments 
had strong therapeutic effects but produced various degrees of 
brain inflammation. In the last group, there was a lasting theras
peutic effect with the least amount of brain inflammation.
cancer epidemioloGY
Thyroid carcinoma in the United Arab Emirates: 
perspectives and experience of a tertiary care 
hospital
AlsZaher and colleagues retrospectively studied the medical res
cords of 135 patients with thyroid carcinoma diagnosed over a 15s
year period, classifying the cases according to the WHO histologic 
classification. They found that 58% were diagnosed before the age 
of 45 years and that the femalestosmale ratio was 2.4:1. Eightys
four percent had papillary thyroid carcinoma, with the convens
tional classical variant the most common type, which is usually 
associated with an iodinessufficient area. Threesquarters of the 
papillary carcinomas presented as multinodular goiter.
cancer patholoGY
Morphologic, immunophenotypic and clinical 
discriminators between T-cell/histiocyte-rich large 
B-cell lymphoma and lymphocyte-predominant 
Hodgkin lymphoma
Mourad and colleagues reviewed 58 cases of Tscell/histiocytesrich 
large B cell lymphoma (THRLBCL) (n=30) and lymphocytes
predominant Hodgkin lymphoma (LPHL) (n=28) to determine 
histomorphologic, immunophenotypic and clinical information 
that might help differentiate between the two entities. They found 
that a combination of multiple parameters can help differentis
ate between the two diseases. Two cases originally diagnosed as 
LPHL were resassigned the diagnosis of TCHRLBCL.
cancer chemotherapY
A retrospective comparison of concurrent bolus 
5-fluorouracil or raltitrexed in preoperative 
chemoradiation for locally advanced rectal cancer
In a retrospective analysis, Yoney and colleagues compared res
sponse rates and toxicity data in 59 patients diagnosed with los
cally advanced rectal cancer and treated with surgery following 
preoperative chemoradiation with either concurrent 5sfluorouras
cil (FU) or raltitrexed (RA). Pathologic complete response rates 
were similar for both regimens (6% with FU, 7% with RA), as was 
sphincter preservation, local control and distant recurrence rates. 
The incidence of downstaging was greater with radiotherapy (RT) 
plus FU, but was also associated with a greater incidence of acute 
grade 2 GIS toxicity. They concluded that FU seems to be the best 
therapeutic choice, while RA seems to be as effective and not sus
perior to bolus FU.
cancer bioloGY
Expression of CD66c and CD25 in acute 
lymphoblastic leukemia as a predictor of the 
presence of BCR/ABL rearrangement
Qwaidah and colleagues evaluated the frequency of expression of 
CD66c and/or CD25 in BCR/ABLspositive cases among 103 
patients diagnosed with presB cell ALL or biphenotypic leukes
mia. All 18 cases positive for BCR/ABL rearrangement, which 
predicts the worse prognosis in adult and pediatric presB cell 
ALL, were positive for both surface CD66c and CD25. Positivity 
for both leukemiasassociated antigens can predict the presence of 
BCL/ABL rearrangement in presB cell ALL, but does not replace 
detection of this abnormality by cytogenetic or molecular techs
niques. It can serve as a handy tool for prediction and manages
ment of highsrisk cases of presB cell ALL, especially in centers 
with limited laboratory facilities.
bioStatiSticS and clinical trialS
Assessing the quality of randomized controlled 
trials from two leading cancer journals using the 
CONSORT statement
Sut and colleagues examined the adherence of 33 randoms
ized controlled trials (RCTs) to 19 methodological items of the 
Consolidated Standards for Reporting Trials (CONSORT) 
statement. Most descriptors of the checklist were methodologis
cally adequate except for sequence generation, allocation conceals
ment, implementation, blinding, sample size, and randomization. 
The authors urge researchers to conform to the CONSORT 
statement when reporting RCTs.
